COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

PHASE2CompletedINTERVENTIONAL

Enrollment

295

Participants

Timeline

Start Date

April 29, 2021

Primary Completion Date

November 21, 2022

Study Completion Date

November 21, 2022

Conditions

HealthyChronic Stable Illness

Interventions

DRUG

casirivimab+imdevimab

Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration

BIOLOGICAL

Moderna mRNA-1273 vaccine

Single intramuscular (IM) injection

Trial Locations (6)

Regeneron Research Site, Orlando

Regeneron Research Site, Hialeah

Regeneron Research Site, Miami

Regeneron Research Site, Dayton

Regeneron Research Site, Little Rock

Regeneron Research Site, Rogers

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY